202-CoV

202-CoV

Vaccine description
Target	SARS-CoV-2
Vaccine type	Protein subunit
Clinical data
Routes of administration	Intramuscular
Identifiers
CAS Number	2699024-52-5[1]

202-CoV is a COVID-19 vaccine candidate developed by Shanghai Zerun Biotechnology Co., Ltd., Walvax Biotech.[2][3][4] It is one of several candidates under development by Walvax.

Development

In May 2020, the Bill & Melinda Gates Foundation awarded Shanghai Zerun Biotechnology a $1,000,000 USD vaccine development grant to "support research and development for COVID-19 response".[5]

In July 2021, the Coalition for Epidemic Preparedness Innovations (CEPI) announced that it had partnered with Shanghai Zerun Biotechnology and its parent company, Walvax Biotech, to develop COVID-19 vaccine candidates against both the original strain of SARS-CoV-2 and its newer variants.[4] As of October 2022, CEPI had provided up to $25.1 million USD towards 202-CoV, but had ceased further funding.[6] The chimeric protein candidate remains in Phase I clinical trials.

References

1. "Patent Landscape Report COVID-19-related vaccines and therapeutics" (PDF).
2. Clinical trial number NCT04982068 for "Phase I Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell)" at ClinicalTrials.gov
3. Clinical trial number NCT04990544 for "Phase II Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell)" at ClinicalTrials.gov
4. "CEPI partners with Shanghai Zerun Biotech to develop COVID-19 variant vaccine". Coalition for Epidemic Preparedness Innovations. 21 July 2021. Retrieved 30 August 2021.
5. "Shanghai Zerun Biotechnology Co., Ltd". Bill & Melinda Gates Foundation. May 2020. Archived from the original on 21 October 2022. Retrieved 21 October 2022.
6. "Our portfolio". Coalition for Epidemic Preparedness Innovations (CEPI). Archived from the original on 21 October 2022. Retrieved 21 October 2022.